What’s the future of vaccines linked to rare clotting disorders?
What’s the future of vaccines linked to rare clotting disorders?
This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.
This article has been translated from its original language. Please reach out if you have any feedback on the translation.
The AstraZeneca vaccine—or Covishield as it is also known—is the cornerstone of the global scheme aimed at vaccinating billions in the developing world. The Johnson & Johnson vaccine is expected to provide hundreds of millions of doses to this effort as well. But both have been tarred with reports of serious but very rare cases of blood clots. So what are the implications for vaccine efforts in the developing world?
The AstraZeneca vaccine—or Covishield as it is also known—is the cornerstone of the global scheme aimed at vaccinating billions in the developing world. The Johnson & Johnson vaccine is expected to provide hundreds of millions of doses to this effort as well. But both have been tarred with reports of serious but very rare cases of blood clots. So what are the implications for vaccine efforts in the developing world?
